10-Q for Q3 FY2026, filed Nov 10, 2026
−$25.1MView ↗
8-K, filed Jul 14, 2026
The Company currently intends to use the net proceeds from the Offering, together with its current cash and cash equivalents, to accelerate…View ↗
8-K, filed Apr 1, 2026
Based on these results, the Company does not plan to independently advance ALTO-101 in CIAS and will instead prioritize resources toward…View ↗
Loading...